BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32683126)

  • 1. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
    Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.
    Getz KD; Alonzo TA; Sung L; Meshinchi S; Gerbing RB; Raimondi S; Hirsch B; Loken M; Brodersen LE; Kahwash S; Choi J; Kolb EA; Gamis A; Aplenc R
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29313. PubMed ID: 34472213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
    De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
    Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
    Horton TM; Perentesis JP; Gamis AS; Alonzo TA; Gerbing RB; Ballard J; Adlard K; Howard DS; Smith FO; Jenkins G; Kelder A; Schuurhuis GJ; Moscow JA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1754-60. PubMed ID: 24976003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
    J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
    Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
    Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.
    Orgel E; Zung L; Ji L; Finklestein J; Feusner J; Freyer DR
    Pediatr Blood Cancer; 2013 Sep; 60(9):1528-33. PubMed ID: 23441080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
    Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
    Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
    Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing cardiac toxicity in children with acute myeloid leukemia.
    Narayan HK; Getz KD; Leger KJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
    Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
    J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
    Leger KJ; Robison N; Narayan HK; Smith AM; Tsega T; Chung J; Daniels A; Chen Z; Englefield V; Demissei BG; Lefebvre B; Morrow G; Dizon I; Gerbing RB; Pabari R; Getz KD; Aplenc R; Pollard JA; Chow EJ; Tang WHW; Border WL; Sachdeva R; Alonzo TA; Kolb EA; Cooper TM; Ky B
    Front Cardiovasc Med; 2023; 10():1286241. PubMed ID: 38107263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.
    Kim DS; Kang KW; Lee SR; Park Y; Sung HJ; Kim SJ; Choi CW; Kim BS
    Ann Hematol; 2015 Sep; 94(9):1485-92. PubMed ID: 25944346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.